Company: CNTB
Filing Date: 2025-03-28
Form Type: 6-K
Source: 0001835268-25-000008
Chunk: 0

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-03-28
Form: 6-K
Chunk 0
---
### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549
<div align='center'>______________________________________________________________________</div>

#### FORM 6-K
<div align='center'>______________________________________________________________________</div>

### REPORT OF FOREIGN PRIVATE ISSUER

#### PURSUANT TO RULE 13a-16 OR 15d-16

#### UNDER THE SECURITIES EXCHANGE ACT OF 1934

#### For the month of March 2025.
<div align='center'>______________________________________________________________________</div>

#### Commission File Number: 001-40212
<div align='center'>______________________________________________________________________</div>

#### Connect Biopharma Holdings Limited
<div align='center'>(Translation of registrant’s name into English)

______________________________________________________________________</div>

#### 3580 Carmel Mountain Road, Suite 200

#### San Diego, California 92130, USA
<div align='center'>(Address of principal executive office)

______________________________________________________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐</div>

#### INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On March 28, 2025, Connect Biopharma Holdings Limited (the “Company”) issued a press release announcing that it received a letter dated March 24, 2025 from the Listings Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), indicating that, for the last thirty consecutive business days, the bid price for the Company’s American Depositary Shares (“ADSs”) had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until September 22, 2025 (the first business day after the 180-day period), to regain compliance with the Minimum Bid Price Requirement. The letter states that the Nasdaq staff will provide written confirmation of compliance if at any time during this 180-day period, the closing bid price of the Company’s ADSs is at least $1.00 for a